EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Roles of programmed death‐1 and muscle innate lymphoid cell‐derived interleukin 13 in sepsis‐induced intensive care unit‐acquired weakness

Yuichi Akama iD, Eun Jeong Park iD, Naoko Satoh-Takayama, Atsushi Ito, Eiji Kawamoto iD, Arong Gaowa, Eri Matsuo, Satoshi Oikawa iD, Masafumi Saito, Shigeaki Inoue, Takayuki Akimoto, Kei Suzuki und 1 weitere

Journal of Cachexia, Sarcopenia and Muscle · 2024

DOI: 10.1002/jcsm.13548 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2024. Verfasst von Yuichi Akama und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pathobiology and Cell Adhesion Biology, Mie University Graduate School of Medicine, Tsu, Japan. Hauptthemen laut MEDLINE: Interleukin-13, Mice, Knockout, Muscle Weakness, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI, Takeda Science Foundation, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intensive care unit‐acquired weakness (ICU‐AW) is a syndrome characterized by a long‐term muscle weakness often observed in sepsis‐surviving patients during the chronic phase. Although ICU‐AW is independently associated with increased mortality, effective therapies have yet to be established. Programmed death‐1 (PD‐1) inhibitors have attracted attention as potential treatments for reversing immune exhaustion in sepsis; however, its impact on ICU‐AW remains to be elucidated. Here, we study how PD‐1 deficiency affects sepsis‐induced skeletal muscle dysfunction in a preclinical sepsis model.

Methods

Chronic sepsis model was developed by treating wild‐type (WT) and PD‐1 knockout (KO) mice with caecal slurry, followed by resuscitation with antibiotics and saline. Mice were euthanized on days 15–17. Body weights, muscle weights, and limb muscle strengths were measured. Interleukin 13 (IL‐13) and PD‐1 expressions were examined by flow cytometry. Messenger RNA (mRNA) expressions of slow‐twitch muscles were measured by reverse transcription and quantitative polymerase chain reaction (RT‐qPCR). In an in vitro study, C2C12 myotubes were treated with lipopolysaccharide (LPS) and recombinant IL‐13 followed by gene expression measurements.

Results

WT septic mice exhibited decreased muscle weight (quadriceps, P < 0.01; gastrocnemius, P < 0.05; and tibialis anterior, P < 0.01) and long‐term muscle weakness ( P < 0.0001), whereas PD‐1 KO septic mice did not exhibit any reduction in muscle weights and strengths. Slow‐twitch specific mRNAs, including myoglobin ( Mb ), troponin I type 1 ( Tnni1 ), and myosin heavy chain 7 ( Myh7 ) were decreased in WT skeletal muscle ( Mb , P < 0.0001; Tnni1 , P < 0.05; and Myh7 , P < 0.05) after sepsis induction, but mRNA expressions of Tnni1 and Myh7 were increased in PD‐1 KO septic mice ( Mb , not significant; Tnni1 , P < 0.0001; and Myh7 , P < 0.05). Treatment of C2C12 myotube cells with LPS decreased the expression of slow‐twitch mRNAs, which was restored by IL‐13 ( Mb , P < 0.0001; Tnni1 , P < 0.001; and Myh7 , P < 0.05). IL‐13 production was significantly higher in ILC2s compared to T cells in skeletal muscle ( P < 0.05). IL‐13‐producing ILC2s in skeletal muscle were examined and found to increase in PD‐1 KO septic mice, compared with WT septic mice ( P < 0.05). ILC2‐derived IL‐13 was increased by PD‐1 KO septic mice and thought to protect the muscles from experimental ICU‐AW.

Conclusions

Long‐term muscle weakness in experimental ICU‐AW was ameliorated in PD‐1 KO mice. ILC2‐derived IL‐13 production in skeletal muscles was increased in PD‐1 KO mice, thereby suggesting that IL‐13 alleviates muscle weakness during sepsis. This study demonstrates the effects of PD‐1 blockade in preserving muscle strength during sepsis through an increase in ILC2‐derived IL‐13 and may be an attractive therapeutic target for sepsis‐induced ICU‐AW.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-13Mice, KnockoutMuscle WeaknessProgrammed Cell Death 1 ReceptorSepsisAnimalsMaleMiceDisease Models, AnimalImmunity, InnateIntensive Care UnitsLymphocytesMuscle, Skeletal

Stichwörter der Autor:innen

Group 2 innate lymphoid cell (ILC2)ICU‐AWIL‐13PD‐1SepsisSlow‐twitch

Substanzen

Interleukin-13Pdcd1 protein, mouseProgrammed Cell Death 1 ReceptorIl13 protein, mouse

Autor:innen und Institutionen

  • Department of Molecular Pathobiology and Cell Adhesion Biology, Mie University Graduate School of Medicine, Tsu, Japan.
  • Department of Emergency and Critical Care Medicine, Mie University Graduate School of Medicine, Tsu, Japan.
  • Precision Immune Regulation RIKEN Research Unit, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan.
  • Department of Thoracic and Cardiovascular Surgery, Mie University Graduate School of Medicine, Tsu, Japan.
  • Faculty of Sport Sciences, Waseda University, Saitama, Japan.
  • Department of Disaster and Emergency and Critical Care Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

ORCID-Profile: Yuichi Akama, Eun Jeong Park, Eiji Kawamoto, Satoshi Oikawa

Förderung

  • JSPS KAKENHI
  • Takeda Science Foundation
  • Japan Society for the Promotion of Science

Zitieren

APA

Akama, Y., Park, E. J., Satoh-Takayama, N., Ito, A., Kawamoto, E., Gaowa, A., Matsuo, E., Oikawa, S., Saito, M., Inoue, S., Akimoto, T., Suzuki, K., & Shimaoka, M. (2024). Roles of programmed death‐1 and muscle innate lymphoid cell‐derived interleukin 13 in sepsis‐induced intensive care unit‐acquired weakness. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13548

Vancouver

Akama Y, Park EJ, Satoh-Takayama N, Ito A, Kawamoto E, Gaowa A, et al. Roles of programmed death‐1 and muscle innate lymphoid cell‐derived interleukin 13 in sepsis‐induced intensive care unit‐acquired weakness. Journal of Cachexia, Sarcopenia and Muscle. 2024. doi:10.1002/jcsm.13548

BibTeX
@article{Akama2024,
  author = {Akama, Yuichi and Park, Eun Jeong and Satoh-Takayama, Naoko and Ito, Atsushi and Kawamoto, Eiji and Gaowa, Arong and Matsuo, Eri and Oikawa, Satoshi and Saito, Masafumi and Inoue, Shigeaki and Akimoto, Takayuki and Suzuki, Kei and Shimaoka, Motomu},
  title = {Roles of programmed death‐1 and muscle innate lymphoid cell‐derived interleukin 13 in sepsis‐induced intensive care unit‐acquired weakness},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2024},
  doi = {10.1002/jcsm.13548}
}
Kostenlos starten →